Danielle El-Haddad

Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience.

E. Shpall, R. Chemaly, E. Ariza-Heredia, 2016, Antiviral research.

The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients

E. Shpall, K. Rezvani, R. Chemaly, 2018, The Journal of infectious diseases.